John Cox - 16 Jul 2025 Form 4 Insider Report for Dyne Therapeutics, Inc. (DYN)

Reporting relationship: CEO & President, Director
Issuer ticker: DYN
Reported as of: 16 Jul 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Jul 2025, 17:19:53 UTC
Prior SEC filing: 15 Jul 2025
Next SEC filing: 09 Sep 2025
Source filing: View source filing
Reporting owner signature: /s/ Ron Caponigro, Attorney-in-Fact

Key filing fact

John Cox filed Form 4 for Dyne Therapeutics, Inc. (DYN) on 18 Jul 2025.

Key facts

This page summarizes John Cox's Form 4 filing for Dyne Therapeutics, Inc. (DYN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 18 Jul 2025, 17:19.

Change

Previous filing in this sequence was filed on 15 Jul 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001498428 Primary reporting owner

Cox John

Relationship: CEO & President, Director
Address: C/O DYNE THERAPEUTICS, INC., 1560 TRAPELO ROAD, WALTHAM
Signature: /s/ Ron Caponigro, Attorney-in-Fact
Signature date: 18 Jul 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DYN transaction Derivative

Stock option (right to buy)

Award

Transaction value: $0
Shares: +197,285
Change %
Price: $0.000000
Shares after: 197,285
Date: 16 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 197,285
Exercise price: $9.33
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option was granted on July 16, 2025 (the "Grant Date"). The shares underlying the option are scheduled to vest over three years, with 50% of the shares underlying the grant vesting 18 months after the Grant Date and with the balance of the shares underlying the grant vesting in equal quarterly installments thereafter; provided that such option shall not be exercisable unless and until (i) the average closing price of the common stock on the Nasdaq Global Select Market over a 20 consecutive trading day period equals or exceeds $20.00 per share at any time during the three-year period following the Grant Date (the "Performance Period") or (ii) a Change in Control (as defined in the Issuer's Amended and Restated Executive Severance and Change in Control Benefits Plan) is consummated during the Performance Period pursuant to which a third party acquires the common stock for a price per share that the Board of Directors of the Issuer determines equals or exceeds $20.00 per share.